Symbiotec Pharmalab IPO GMP History
Final pre-listing GMP reading: 1 Sept 2026, 5:00 am IST
GMP applies before listing only. The figures below are a historical record of grey market sentiment ahead of the debut on 1 Sept 2026 — see listing performance for the actual outcome.
GMP trend
GMP moved from ₹0 on 18 Aug 2026 to ₹185 on 1 Sept 2026.
Day-wise GMP history
| Date | GMP | Implied Return | Subject to Sauda | Implied Listing |
|---|---|---|---|---|
| 1 Sept 2026 | ₹185 | +18.7% | — | ₹1,173 |
| 31 Aug 2026 | ₹198 | +20.0% | ₹2,100 | ₹1,186 |
| 30 Aug 2026 | ₹240 | +24.3% | ₹2,700 | ₹1,228 |
| 29 Aug 2026 | ₹242 | +24.5% | ₹2,700 | ₹1,230 |
| 28 Aug 2026 | ₹265 | +26.8% | ₹3,000 | ₹1,253 |
| 27 Aug 2026 | ₹270 | +27.3% | ₹3,100 | ₹1,258 |
| 26 Aug 2026 | ₹315 | +31.9% | ₹3,200 | ₹1,303 |
| 25 Aug 2026 | ₹352 | +35.6% | ₹4,000 | ₹1,340 |
| 24 Aug 2026 | ₹365 | +36.9% | ₹3,800 | ₹1,353 |
| 23 Aug 2026 | ₹409 | +41.4% | ₹4,700 | ₹1,397 |
| 22 Aug 2026 | ₹410 | +41.5% | ₹4,700 | ₹1,398 |
| 21 Aug 2026 | ₹345 | +34.9% | ₹3,900 | ₹1,333 |
| 20 Aug 2026 | ₹270 | +27.3% | ₹3,400 | ₹1,258 |
| 19 Aug 2026 | ₹220 | +22.3% | ₹2,500 | ₹1,208 |
| 18 Aug 2026 | ₹0 | +0.0% | — | ₹988 |
GMP is an unofficial figure sourced from grey market dealers and is not a guarantee of the listing price. Provided for information only, not investment advice. How we source GMP · Disclaimer
Reading this GMP history
How the GMP moved
The first grey market reading in our record for the Symbiotec Pharmalab IPO came in at ₹0 on 18 Aug 2026. The premium peaked at ₹410, roughly +41.5% on the issue price on 22 Aug 2026. The final reading before listing was ₹185, dated 1 Sept 2026. Start to finish, over 15 days, that is a net rise of ₹185 per share. Day-end readings ranged between ₹0 and ₹410 across 15 days of data — a band of ₹410 that shows how much dealer sentiment shifted while the quote was live.
GMP versus the actual listing
Going into listing day, the final premium of ₹185 implied a debut near ₹1,173 against the issue price of ₹988. The stock actually debuted at ₹978.2, a listing loss of -1.0% on the issue price. That puts the actual debut ₹194.8 below what the final premium implied — a gap worth noting when weighing how much signal GMP carried for this issue.
Kostak and subject-to-sauda
The grey market in this issue went beyond the share premium to application-level deals. The subject-to-sauda rate — what a buyer pays for an application that is honoured only if it wins allotment — was last quoted at ₹2,100 per application as of 31 Aug 2026. Unlike a kostak deal, where an application changes hands at a fixed price regardless of the outcome, a sauda payout depends entirely on the allotment draw. At the prevailing premium, the dealer-estimated profit per lot stood at ₹2,775 on a lot of 15 shares. Both metrics come from the same dealer network as the GMP itself and move with it. Every grey market figure on this page is an unofficial number collected from grey-market dealers; it is not published by the company or the exchanges and is not a guarantee of the actual listing price.
Frequently asked questions
- What is the Symbiotec Pharmalab IPO price band?
- The Symbiotec Pharmalab IPO price band is ₹938 to ₹988 per share, with a lot size of 15 shares.
- What was the Symbiotec Pharmalab IPO GMP before listing?
- The final grey market premium recorded before the Symbiotec Pharmalab IPO listed was ₹185. The IPO listed on 1 Sept 2026 at ₹978.2, -1.0% against the issue price. GMP is an unofficial figure and was never a guarantee of the listing price.
- When is the Symbiotec Pharmalab IPO allotment and listing date?
- Allotment is expected on 28 Aug 2026. The shares are scheduled to list on 1 Sept 2026 on NSE and BSE.